MaaT Pharma Company Description

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment.

The company was incorporated in 2014 and is headquartered in Lyon, France.

MaaT Pharma SA

Country	France
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	60
CEO	Herve Affagard

Contact Details

Address: 70 Avenue Tony Garnier Lyon, Auvergne 69007 France
Phone	33 4 28 29 14 00
Website	maatpharma.com

Stock Details

Ticker Symbol	MAAT
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0012634822
SIC Code	2836

Key Executives

Name	Position
Herve Affagard	Chief Executive Officer, Co-Founder and Director
Dr. Joel Dore Ph.D.	Co-Founder and Member of Scientific Advisory Board
Pierre Rimbaud	Co-Founder
Eric Soyer Ph.D.	Chief Financial Officer
Carole Schwintner	Technology Director and Chief Technology Officer
Guilhaume Debroas Ph.D.	Head of Investor Relations
Sian Crouzet	Chief of Staff
Dr. Emilie Plantamura	Head of Clinical Development
Jonathan Chriqui Pharm.D.	Chief Business Officer
Dr. Gianfranco Pittari M.D., Ph.D.	Chief Medical Officer